A phase 1 study of NBI-1070770 for treatment of Major Depressive Disorder
Latest Information Update: 09 Nov 2022
Price :
$35 *
At a glance
- Drugs NBI-1070770 (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- 09 Nov 2022 New trial record